Methylene Blue for Vasoplegia During Extracorporeal Membrane Oxygenation Support

Ortoleva, Jamel; Roberts, Russel J.; Devine, Lauren T.; French, Amy; Kawabori, Masashi; Chen, Fredrick; Shelton, Kenneth; Dalia, Adam A.

doi:10.1053/j.jvca.2020.12.042

Cited by 13 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pankaj Garg 1 , John H. Yazji 2 , Emad Alamouti-Fard 2 , Ishaq Wadiwala *Address all correspondence to: jacob.samuel@mayo.edu vasopressin, and epinephrine to counteract vasoplegia. In case of suboptimal effect, agents such as methylene blue, hydroxycobalamin, and angiotensin II should be considered [168,169].…”

Section: Author Detailsmentioning

confidence: 99%

Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock

Garg¹,

Yazji²,

Alamouti-Fard³

et al. 2023

Management of Shock - Recent Advances

View full text Add to dashboard Cite

In the United States, ~100,000 patients are hospitalized annually for cardiogenic shock with 27–51% mortality. Similarly, ~356,000 patients develop out-of-hospital cardiac arrests (OHCA) annually with 90% mortality. In the last few decades, several acute mechanical circulatory support (AMCS) devices have been developed to provide hemodynamic support and to improve outcomes in patients with cardiogenic shock and cardiac arrest. Among all the devices, venoarterial extracorporeal membrane oxygenation (VA-ECMO) is the only AMCS device that provides immediate and complete cardiopulmonary support. With an increase in clinical experience with VA-ECMO, use of VA-ECMO has expanded beyond post-cardiotomy cardiogenic shock. In the last two decades, there has also been a rapid growth in the observational and randomized data describing the clinical and logistical considerations with successful clinical outcomes in patients with cardiogenic shock and cardiac arrest. In this review, we discuss the fundamental concepts and hemodynamic aspects of VA-ECMO, its indications, contraindications, and the complications that are encountered in the setting of VA-ECMO in patients with cardiac arrest and cardiogenic shock of various etiologies.

show abstract

Section: Author Detailsmentioning

confidence: 99%

Overview of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiac Arrest and Cardiogenic Shock

Garg¹,

Yazji²,

Alamouti-Fard³

et al. 2023

Management of Shock - Recent Advances

View full text Add to dashboard Cite

show abstract

“…*Address all correspondence to: jacob.samuel@mayo.edu vasopressin, and epinephrine to counteract vasoplegia. In case of suboptimal effect, agents such as methylene blue, hydroxycobalamin, and angiotensin II should be considered [168,169].…”

Section: Conflict Of Interestmentioning

confidence: 99%